%0 Journal Article
%T Efficacy of Biosimilars in Psoriasis
%A Grace Kimmel
%A Michael Tyutyunik
%J Journal of Psoriasis and Psoriatic Arthritis
%@ 2475-5311
%D 2019
%R 10.1177/2475530319826568
%X Biologic therapies have revolutionized the treatment of moderate-to-severe psoriasis, and several biologic agents are currently available to patients. However, the high cost associated with these drugs contributes to the underutilization of biologics and the resultant undertreatment of disease. In recent years, biosimilars have been developed for several of the commonly used biologic agents, with reported similar efficacy and safety profiles to the original agents. They are also somewhat less costly than the original biologic agents that they are similar to. Despite this, many dermatologists are still skeptical of biosimilars for a variety of reasons. It is important for dermatologists to familiarize themselves with the emerging safety and efficacy data for the biosimilar agents, so as to provide patients with safe, efficacious, and potentially affordable treatment options as biosimilars become available over the next several years. In this article, we set out to review available data regarding biosimilar medications in the treatment of psoriasis. A literature review was performed utilizing the PubMed database. The results of these studies indicate that biosimilars have a high degree of similarity regarding safety and efficacy when compared to their originator biologics for the treatment of psoriasis
%K psoriasis
%K biologic
%K biosimilar
%K adalimumab
%K infliximab
%U https://journals.sagepub.com/doi/full/10.1177/2475530319826568